Immutep is a late-stage biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Australia, Europe and the United States.

The Company is a global leader in Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells. Immutep’s clinical portfolio harnesses the power of patients own immune systems.

Immutep, formerly Prima BioMed, was originally created as a mining company (Prima Resources) in Australia in 1987, and was first publicly traded in 1988 on the Australian Stock Exchange. The Company was repositioned as a biotechnology company in 2001 following the acquisition of the rights to develop technologies from the Austin Research Institute (now the Burnet Institute).

On 2 October 2014, Prima BioMed announced the acquisition of Immutep SA, a private French biotechnology company. The transaction was formalised at the Annual General Meeting of shareholders on 14 November 2014 and completed on 17 December 2014. On 1 December 2017, Prima BioMed changed its name to Immutep Limited following shareholder approval at the Annual General Meeting on 17 November 2017.

Immutep’s corporate headquarters are in Sydney, Australia. Immutep also has operations in Germany, France and the United States.

Immutep Limited (Immutep) is listed on the Australian Securities Exchange (ASX) under the ticker, IMM. The ASX is the home market of Immutep and the exchange on which its ordinary shares can be traded.

Immutep has a secondary listing on the NASDAQ under the ticker, IMMP. Immutep’s American Depositary Receipts (ADRs) are listed on the NASDAQ.

For more information on ADRs please visit:
www.adrbnymellon.com/resources/dr-basics

Each ADR represents 10 Immutep Limited ordinary fully paid shares. For further details on Immutep’s ADRs please visit:
https://www.adrbny.com/content/adr/us/en/directory/dr-directory.html

LAG-3 stands for Lymphocyte Activation Gene-3 (LAG-3 or CD223), a protein which in humans is encoded by the LAG-3 gene. It is a cell surface molecule, which is involved in the regulation of T cells.

The LAG-3 protein controls the signaling between T cells and antigen presenting cells (APC’s). It has a unique dual mechanism of action, as an APC activator to stimulate the immune response and, in other applications, as a negative regulator of T cells to switch off the immune response.

Immutep has four clinical stage candidates and one candidate that is early-stage. The lead product candidate eftilagimod alfa (efti) is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with anti-PD-[L]1 immunotherapy and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA).

Efti is Immutep’s proprietary soluble LAG-3 clinical stage candidate that is a first-in-class antigen-presenting cell (APC) activator that stimulates both innate and adaptive immunity for the treatment of cancer. Efti binds to and activates antigen presenting cells via MHC II molecules leading to expansion and proliferation of CD8+ (cytotoxic) T cells, CD4+ (helper) T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like IFN-ƴ and CXCL10 that further boost the immune system’s ability to fight cancer.

Immutep operates as a global company, and therefore, perform R&D in different countries. Clinical research is conducted in Australia, Europe and the United States, and the Company has a laboratory facility in Paris.

Immutep’s current development strategy is to focus on LAG-3 programs in order to bring product candidates to commercialisation, either through its own clinical trials or through various commercial partnerships. This requires ongoing funding and as a clinical stage biotechnology company Immutep continually assesses opportunities for supporting its product pipeline and R&D activities.

Immutep is a globally active biotechnology company developing immunotherapies for cancer and autoimmune diseases. Immutep has a number of collaborations underway with various corporations and academic institutions including:

• Clinical trial collaboration and supply agreements with MSD (Merck US) and Merck KGaA (Darmstadt, Germany)
• License agreements with Novartis (LAG525) and EOC Pharma (eftilagimod alfa in Greater China).
• Additional collaborations or agreements with Labcorp, Maria Skłodowska-Curie National Research Institute, Cardiff University, and Monash University.

Immutep owns or co-owns a total of 13 patent families covering its pipeline of product candidates. In particular, Immutep owns seven families covering eftilagimod alfa (efti). Three of these families are directed to methods of treating cancer and infectious disease with efti alone, or in combination with chemotherapy, a therapeutic antibody acting via ADCC or a PD-1 / PD-L1 inhibitor. Another family is directed to triple combination with efti, chemotherapy and a PD-1/PD-L1 inhibitor, and two families are drawn to the aspects of the AIPAC clinical trials. One further family is directed to a release assay associated with the manufacture of efti.

In addition, Immutep owns three patent families covering IMP731, and co-owns with Novartis two families covering LAG525. The two families covering LAG525 are exclusively licensed to Novartis. Immutep also co-owns a patent family covering GSK’781. This family is co-owned with the National Institute for Health and Medical Research (INSERM).